POS0986 SELF-REPORTED PHYSICAL ACTIVITY IN PATIENTS WITH axSpA: ADHERENCE TO PUBLIC HEALTH RECOMMENDATIONS AND ASSOCIATION WITH HEALTH STATUS IN TWO DUTCH COHORTS
Authors: M. Carbo, B. Hilberdink, D. Paap, F. Wink, T. P. M. Vliet Vlieland, S. Van Weely, A. Spoorenberg, S. Arends
Journal: Annals of the Rheumatic Diseases (2022)

Background In general, regular physical activity (PA) is associated with a reduced risk of cardiovascular disease and all-cause mortality. In people with axial spondyloarthritis (axSpA) specifically, regular PA has shown beneficial effects on function, spinal mobility and pain. The World Health Organization (WHO) developed public health recommendations for the frequency, intensity and duration of PA in adults required to offer significant health benefits and mitigate health risks. Objectives To assess the proportion of axSpA patients fulfilling the WHO PA recommendations and to investigate the association of the amount of PA with health status and quality of life (QoL). Methods Patients from two Dutch cohorts were included; one in the Northern (GLAS cohort, n=148) and one in the Western (LUMC cohort, n=193) part of the Netherlands. The (m)SQUASH was used to assess the type, intensity and time spent on PA during a normal week in the past month. Fulfillment of the WHO PA recommendations was defined as aerobic PA of least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity (or an equivalent combination), and muscle-strengthening activities twice a week. Univariate linear regression analysis was used to explore the association of (m)SQUASH total score with health status (ASAS-HI) and quality of life (ASQoL). Multivariate regression analysis was used to correct these associations for age, gender, BMI and ASDAS as potential confounders. Results In the GLAS cohort, 59% were male, mean age (± SD) was 48.5 ± 13.2 years, median (IQR) ASAS-HI was 4.4 (1.9-8.1) and median ASQoL was 4 (1-9). In the LUMC cohort, 69% were male, mean age was 55.7 ± 14.1 years, and median ASAS-HI was 5.3 (2.1-8.0). Of these GLAS and LUMC patients, 57 (40%) and 62 (35%) fulfilled the WHO PA recommendations, respectively. Total (m)SQUASH score was significantly associated with ASAS-HI (GLAS cohort: R 2 0.16, B (95%CI) -0.4 (-4.3;-1.6); LUMC cohort: R 2 0.13, B (95%CI) -0.3 (-4.3;-2.0)) and ASQoL (GLAS cohort: R 2 0.18, B (95%CI) -4.4 (-3.5;-1.4). These associations remained significant after correcting for age, gender, BMI and ASDAS (Table 1). Table 1. Association between total (m)SQUASH score and health status or quality of life in axSpA patients. ASAS-HI ASQoL R 2 B (95% CI) P-value R 2 B (95% CI) P-value GLAS cohort mSQUASH total score 0.16 -0.4 (-4.3;-1.6) &lt;0.001 0.18 -4.4 (-3.5;-1.4) &lt;0.001 mSQUASH corrected for age, gender 0.19 -0.4 (-0.1;-1.5) &lt;0.001 0.21 -4.2 (-0.9;-1.3) &lt;0.001 mSQUASH corrected for age, gender, BMI, ASDAS 0.30 -4.4 (-6.3;.2.6) &lt;0.001 0.31 -3.4 (-5.1;-1.9) &lt;0.001 LUMC cohort SQUASH total score 0.13 -0.3 (-4.3;-2.0) &lt;0.001 SQUASH corrected for age, gender 0.23 -2.7 (-3.9;-1.6) &lt;0.001 Conclusion In both Dutch cohorts, only 35-40% of axSpA patients fulfilled the WHO PA recommendations, which seems less compared to the average 48% in the Dutch adult population 1 . AxSpA patient reporting a higher level of PA had better health status and QoL. Therefore, in daily clinical practice, greater awareness and focus on moderate-to-high intensity and muscle strengthening activity is desirable for axSpA patients. References [1]Duijvestijn et al. Int J Environ Res Public Health 2020. Acknowledgements The authors would like to thank ASAS and the Dutch Arthritis Society for supporting the original studies within the GLAS and LUMC cohorts. Disclosure of Interests Marlies Carbo: None declared, Bas Hilberdink: None declared, Davy Paap: None declared, Freke Wink: None declared, T.P.M. Vliet Vlieland: None declared, Salima van Weely: None declared, Anneke Spoorenberg Paid instructor for: AbbVie, Consultant of: AbbVie, Novartis Pharma, Pfizer, UCB Pharma, Lilly, Grant/research support from: Novartis Pharma, Pfizer, Suzanne Arends: None declared